JP Morgan Maintains Overweight on Repligen, Lowers Price Target to $200
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Rachel Vatnsdal maintains an Overweight rating on Repligen (NASDAQ:RGEN) but lowers the price target from $230 to $200.
May 02, 2024 | 4:45 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
JP Morgan maintains an Overweight rating on Repligen but reduces the price target from $230 to $200.
The reduction in price target by JP Morgan, despite maintaining an Overweight rating, could lead to short-term negative sentiment among investors, potentially impacting RGEN's stock price negatively.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100